Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$88.17 ▼ -0.96
(-1.08%)
MKT CAP: $22.39B • VOL: 631.9K
52W L $80 52W H $124
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$74
MEDIAN
$99
MEAN
$101
HIGH
$120
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE BNTX TAPE
BNTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $106.69 | $101.40 | 2025-02-14 | $80.23 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $111.09 | $104.04 | 2025-02-06 | $82.88 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $100.51 | $96.99 | 2025-01-29 | $84.64 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $89.93 | — | 2025-01-17 | $86.41 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $77.59 | $83.76 | 2025-01-09 | $78.47 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $104.92 | $91.70 | 2024-12-18 | $76.71 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $85.52 | $89.05 | 2024-12-04 | $82.00 | -4.3% | 48% | C |